<- Go Home
Nkarta, Inc.
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Market Cap
$218.9M
Volume
713.6K
Cash and Equivalents
$27.4M
EBITDA
-$106.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$3.65
52 Week Low
$1.63
Dividend
N/A
Price / Book Value
0.76
Price / Earnings
-2.27
Price / Tangible Book Value
0.76
Enterprise Value
$63.5M
Enterprise Value / EBITDA
-0.66
Operating Income
-$115.3M
Return on Equity
30.07%
Return on Assets
-17.10
Cash and Short Term Investments
$230.4M
Debt
$75.0M
Equity
$285.9M
Revenue
N/A
Unlevered FCF
-$57.4M
Sector
Biotechnology
Category
N/A